Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • Directory of Abstract Indexing for Journals
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences
Journal Flyer
Flyer image
Differentiation of murine dermal papilla cells into myogenic linage for cell-based therapies in Duchenne muscular dystrophy
6th International Conference and Exhibition on Cell and Gene Therapy
March 27-28, 2017 Madrid, Spain

Maral Rashidi, Mahsa Rashidi, Nicholas Rufaut, Maral Rashidi, Heather Gordish-Dressman, Leslie Jones, Terence Partridge and Rodney Sinclair

Shiraz University, Iran
University of Melbourne, Australia
Children´┐Ż??s National Medical Center, USA

Posters & Accepted Abstracts: J Stem Cell Res Ther


Duchenne muscular dystrophy (DMD) is the commonest muscular dystrophy caused by the absence of dystrophin. Stem celltherapy in DMD is one of the most promising approaches for treatment. Multipotent stem cells residing in the hair follicle papilla are highly plastic and are reprogrammable to bone, cartilage, fat, haematopoietic and muscle. Dermal papilla cells (DPC) from the hair follicles of mouse whisker pad were microdissected and cultured. We showed that DPC undergo myogenic differentiation when co-cultured with different types of myoblasts including normal and dystrophic human myoblasts. Lamin A/C staining was used to distinguish DPC- and myoblast-derived myonuclei inside myotubes. DPC incorporated into myotubes has up-regulated the muscle marker myogenin in co-culture with human myoblasts, suggesting that DPC fully underwent myogenic differentiation in these cocultures. We showed that DPC incorporation efficiency was low in all co-cultures and differed significantly between various types of myoblasts. However, no significant difference was observed between normal and dystrophic human myoblasts. These encouraging findings suggested that the altered properties of dystrophic myoblasts did not compromise the myogenic differentiation of DPC in vitro, supporting their in vivo application and possible therapeutic potential. The in vitro effects of galectin-1, reversine and activation of the Shh signaling pathway via recombinant Shh and purmorphamine, on DPC myogenic differentiation were also evaluated. None of the treatments increased myogenin expression in DPC; but triggering Shh-signaling produced a dose-dependent pattern whereby lower levels of signaling promoted myogenic differentiation while higher levels inhibited it. Activating Shh-signaling upstream of Smo via purmorphamine, induced a biphasic differentiative response. However, the application of rShh hindered the differentiation of both cell types. Thus, murine DPC are a readily-accessible source of stem cells that can undergo myogenic differentiation in vitro. We aim to improve their differentiation efficacy to make them suitable candidates for therapeutic applications in muscle wasting disorders.

Biography :

Maral Rashidi is a student at School of Pharmacy at Shiraz University of Medical Sciences, Iran. She has finished her BSc degree in Biochemistry. She is currently undertaking pre-registration clinical trainings at designated pharmacies affiliated to Shiraz University. She is also conducting research on stem cells in collaboration with colleagues from other universities. Her work is focused on evaluating skin stem cells for cell-based therapies in muscular dystrophies. In her work, the effects of varoius dosages of several drugs/treatments on the stem cells differentiation is evaluated. She is also conducting research in the fields of Clinical and Herbal Pharmacology and has gathered data on 100 rare herbal medicines merely found in Iran along with their therapeutic applications. Considerable part of her work is devoted to approach the extrapolation of experimental data to the clinical trials.